Summary of COVID-19 LSALT peptide studies

1. Somayaji et al., Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2 (COVID-19)

61 patient LSALT peptide late treatment RCT: 407% higher mortality (p=0.24) and 7% longer hospitalization (p=0.65).
RCT 61 hospitalised moderate/severe COVID-19 patients showing no significant difference in clinical outcomes with intravenous LSALT peptide treatment.
Mar 2024, BMJ Open, https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2023-076142, https://c19p.org/somayaji